News

Filter by Year

May 07, 2018

London, UK, Carlsbad, CA, 8 May, 2018: GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that GW management will present at the Bank of America Merrill Lynch 2018 Health Care Conference on Tuesday, May 15, 2018 at 1:00 p.m. PT in Las Vegas, Nevada.

A live audio webcast of the presentation…

May 07, 2018

- Positive unanimous vote at Epidiolex® (cannabidiol) FDA Advisory Committee meeting –

- NDA PDUFA goal date scheduled for June 27, 2018 -

- Conference call today at 4:30 p.m. EST -

London, UK, Carlsbad, CA, 8 May 2018: GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a…

May 02, 2018

London, UK, 3 May 2018: GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on 8 May, 2018 its second quarter financial results for the period ending 31 March, 2018. GW will also host a conference call the same day at 4:30 p.m. EDT. Conference call information will be provided in the financial results…

Apr 17, 2018

London, UK, Carlsbad, CA, April 19, 2018 – GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along with its U.S. subsidiary Greenwich Biosciences, today announced that the Peripheral and Central Nervous System Drugs Advisory Committee of the U.S. Food and Drug…

Apr 11, 2018

- Long-Term Safety and Efficacy Data in Patients with

Lennox-Gastaut Syndrome and Dravet Syndrome to be Presented -

London, UK, 12 April 2018: GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along with its U.S.…